Market Overview:
The global tardive dyskinesia market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of tardive dyskinesia, rising geriatric population, and growing demand for better treatment options. The dopamine-depleting medications segment is expected to dominate the global tardive dyskinesia market during the forecast period. This segment is expected to grow at a CAGR of 5.8% from 2018 to 2030 due to the high prevalence of dopamine-depleting medications across different regions. The GABA receptor agonist medications segment is projected to grow at a CAGR of 5.4% from 2018to 2030 due its potential benefits over other treatment options available in the market.
Product Definition:
Tardive dyskinesia is a neurological disorder characterized by involuntary movements of the face and body. It is most often caused by long-term use of antipsychotic medications, but can also be associated with other drugs, brain injuries, and diseases. Tardive dyskinesia can cause difficulty speaking, swallowing, and breathing. It may also lead to social isolation and depression. There is no cure for tardive dyskinesia, but treatments are available to help lessen its symptoms.
Dopamine-Depleting Medications:
Dopamine-depleting medications are used to treat diseases such as Parkinson's disease, dystonia, and Huntington's Chorea. These drugs act by decreasing the production of dopamine in the brain. Dopamine is a chemical messenger that helps control and regulate movement, emotions, sensation & consciousness.
The global market for dopamine-depleting medications was valued at over USD 1 billion in 2015.
GABA Receptor Agonist Medications:
GABA receptor agonist medications are used to treat the symptoms of tardive dyskinesia. The most commonly prescribed drugs are Abilify and Amantadine. These drugs work by decreasing the activity in the brain that causes unwanted movement or twitching.
Application Insights:
The hospitals segment dominated the global tardive dyskinesia market in 2017. This can be attributed to factors such as a high prevalence of elderly patients and a large number of hospital-acquired devices. For instance, according to the National Center for Biotechnology Information (NCBI) in 2015, nearly 20% of all antipsychotics were prescribed for treatment of schizophrenia in outpatient settings and 10% were used primarily in institutionalized care settings. The aforementioned statistics indicate that there are likely to be many more patients suffering from tardive dyskinesia who are being treated outside hospitals than within them owing to non-inclusion of these disorders in insurance coverage or under-reporting by healthcare professionals.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high patient awareness levels coupled with easy access to novel and effective treatment methods for tardive dyskinesia. The introduction ofripavacainumabin March 2018 by Otsuka Pharmaceutical Co., Ltd is expected to further boost the regional market growth over the forecast period.
Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to increasing government initiatives for tackling mental health issues along with growing consumer awareness regarding available treatments in emerging countries such as China and India. In addition, rising prevalence of neurodegenerative disorders such as Parkinson’s disease (PD) and Huntington’s disease (HD), increasing disposable income, availability & adoption of new technologies are some other factors driving this regional market growth overthe next eight years.
Growth Factors:
- Increasing prevalence of neurological disorders: The global prevalence of neurological disorders is increasing at a significant rate. This is primarily owing to the changing lifestyle and environmental factors. Tardive dyskinesia is a neurological disorder that affects the movement of muscles and results in abnormal movements such as twitching, jerking, and writhing movements. As a result, there is an increasing demand for treatments for tardive dyskinesia.
- Growing awareness about tardive dyskinesia: There is growing awareness about tardive dyskinesia among people across the globe due to increased media coverage and research on the condition. This has led to an increase in the number of people seeking treatment for tardive dyskinesia.
- Development of new therapies: There has been considerable progress in the development of new therapies for treating tardive dyskinesia in recent years. These therapies are more effective and have fewer side effects than older therapies available for treating this condition .This is likely to lead to an increase in demand for treatments for tardive dyskinesia in coming years .
Scope Of The Report
Report Attributes
Report Details
Report Title
Tardive Dyskinesia Market Research Report
By Type
Dopamine-Depleting Medications, GABA Receptor Agonist Medications, Anticholinergic Medications
By Application
Hospitals, Ambulatory Surgical Centers, Diagnostic Centers
By Companies
Bausch Health, Neurocrine Biosciences, Teva Pharmaceuticals Industries
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
138
Number of Tables & Figures
97
Customization Available
Yes, the report can be customized as per your need.
Global Tardive Dyskinesia Market Report Segments:
The global Tardive Dyskinesia market is segmented on the basis of:
Types
Dopamine-Depleting Medications, GABA Receptor Agonist Medications, Anticholinergic Medications
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Centers, Diagnostic Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bausch Health
- Neurocrine Biosciences
- Teva Pharmaceuticals Industries
Highlights of The Tardive Dyskinesia Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Dopamine-Depleting Medications
- GABA Receptor Agonist Medications
- Anticholinergic Medications
- By Application:
- Hospitals
- Ambulatory Surgical Centers
- Diagnostic Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tardive Dyskinesia Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tardive dyskinesia is a movement disorder that most often affects the mouth, tongue, and jaw. It can cause involuntary movements of these body parts that can be very difficult to control.
Some of the key players operating in the tardive dyskinesia market are Bausch Health, Neurocrine Biosciences, Teva Pharmaceuticals Industries.
The tardive dyskinesia market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tardive Dyskinesia Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Tardive Dyskinesia Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Tardive Dyskinesia Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Tardive Dyskinesia Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Tardive Dyskinesia Market Size & Forecast, 2020-2028 4.5.1 Tardive Dyskinesia Market Size and Y-o-Y Growth 4.5.2 Tardive Dyskinesia Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Dopamine-Depleting Medications
5.2.2 GABA Receptor Agonist Medications
5.2.3 Anticholinergic Medications
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Ambulatory Surgical Centers
6.2.3 Diagnostic Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tardive Dyskinesia Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tardive Dyskinesia Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Dopamine-Depleting Medications
9.6.2 GABA Receptor Agonist Medications
9.6.3 Anticholinergic Medications
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Ambulatory Surgical Centers
9.10.3 Diagnostic Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Dopamine-Depleting Medications
10.6.2 GABA Receptor Agonist Medications
10.6.3 Anticholinergic Medications
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Ambulatory Surgical Centers
10.10.3 Diagnostic Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Dopamine-Depleting Medications
11.6.2 GABA Receptor Agonist Medications
11.6.3 Anticholinergic Medications
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Ambulatory Surgical Centers
11.10.3 Diagnostic Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Dopamine-Depleting Medications
12.6.2 GABA Receptor Agonist Medications
12.6.3 Anticholinergic Medications
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Ambulatory Surgical Centers
12.10.3 Diagnostic Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Dopamine-Depleting Medications
13.6.2 GABA Receptor Agonist Medications
13.6.3 Anticholinergic Medications
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Ambulatory Surgical Centers
13.10.3 Diagnostic Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tardive Dyskinesia Market: Competitive Dashboard
14.2 Global Tardive Dyskinesia Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bausch Health
14.3.2 Neurocrine Biosciences
14.3.3 Teva Pharmaceuticals Industries